Fiche société
Peking University Third Hospital
Traitements, essais et publications liés.
Traitements8programmes
Essais4liés
Publications9liées
SourceDBlocale
Traitements
8| Molécule | Indication / population | Phase | Objectif | Pays | Résultat |
|---|---|---|---|---|---|
| IM19 CAR-T cellsThe study is a single-arm, open-label clinical trial intended to recruit 6 refractory SLE subjects who meet the inclusion and exclusion criteria. The subjects will receive IM19 CAR-T cell infusion therapy at a dose of 1×10\^6/kg or 1×10\^8 CAR-T cells . The primary endpoint is to evaluate the improvement in SLE disease activity (SLEDAI-2K) at 90 days and the occurrence of adverse events related to IM19 CAR-T cell infusion within 28 days post-infusion. Additionally, the long-term efficacy was evaluated, including the improvement of SLEDAI-2K score and achieving lupus low disease activity (LLDAS) at day 180 and day 360, and renal response at day 180 and day 360. The persistence and duration of IM19 CAR-T cells in the peripheral blood of subjects will also be evaluated. The study plan includes five phases: screening phase, cell collection phase, lymphodepletion pretreatment phase, cell infusion phase, and follow-up phase. | Lupus | Non applicable | Thérapie cellulaire + Immunomodulation | China | À vérifier |
| Natural History and Clinical Features of Amyotrophic Lateral Sclerosis (ALS)Description non affichée : incohérence de maladie détectée. Consultez l’essai clinique officiel associé. | Sclérose latérale amyotrophique | À vérifier | À vérifier | China | À vérifier |
| Peripheral Neurofilament Levels and Amyotrophic Lateral SclerosisDescription non affichée : incohérence de maladie détectée. Consultez l’essai clinique officiel associé. | Sclérose latérale amyotrophique | À vérifier | Neuroprotection | China | À vérifier |
| Transcranial Magnetic StimulationThis study is a randomized, crossover, controlled, double-blind clinical trial. Patients (n=45) were randomly divided into Group A and Group B. Patients in Group A will receive 2 weeks (10800 Hz daily, 5 days×2) of Transcranial magnetic stimulation（TMS） treatment, while patients in Group B will receive sham stimulation with the same frequency. After a 4-week washout period, the two groups cross over. Patients in Group A will receive sham stimulation, and patients in Group B will receive TMS treatment for 2 weeks (10800 Hz daily, 5 days×2). Clinical functional scales, imaging evaluations, and gait analysis will be conducted at baseline, after 2 weeks of treatment, before crossover treatment, and after 2 weeks of crossover treatment. The therapist, patients, and assessors will be all blinded throughout the study. | Sclérose latérale amyotrophique | Phase 1 | À vérifier | À vérifier | |
| Natural History and Clinical Features of Amyotrophic Lateral Sclerosis (ALS)Description non affichée : incohérence de maladie détectée. Consultez l’essai clinique officiel associé. | Sclérose latérale amyotrophique | À vérifier | À vérifier | China | À vérifier |
| Peripheral Neurofilament Levels and Amyotrophic Lateral SclerosisDescription non affichée : incohérence de maladie détectée. Consultez l’essai clinique officiel associé. | Sclérose latérale amyotrophique | À vérifier | Neuroprotection | China | À vérifier |
| Transcranial Magnetic StimulationThis study is a randomized, crossover, controlled, double-blind clinical trial. Patients (n=45) were randomly divided into Group A and Group B. Patients in Group A will receive 2 weeks (10800 Hz daily, 5 days×2) of Transcranial magnetic stimulation（TMS） treatment, while patients in Group B will receive sham stimulation with the same frequency. After a 4-week washout period, the two groups cross over. Patients in Group A will receive sham stimulation, and patients in Group B will receive TMS treatment for 2 weeks (10800 Hz daily, 5 days×2). Clinical functional scales, imaging evaluations, and gait analysis will be conducted at baseline, after 2 weeks of treatment, before crossover treatment, and after 2 weeks of crossover treatment. The therapist, patients, and assessors will be all blinded throughout the study. | Sclérose latérale amyotrophique | Phase 1 | À vérifier | À vérifier | |
| IM19 CAR-T cellsThe study is a single-arm, open-label clinical trial intended to recruit 6 refractory SLE subjects who meet the inclusion and exclusion criteria. The subjects will receive IM19 CAR-T cell infusion therapy at a dose of 1×10\^6/kg or 1×10\^8 CAR-T cells . The primary endpoint is to evaluate the improvement in SLE disease activity (SLEDAI-2K) at 90 days and the occurrence of adverse events related to IM19 CAR-T cell infusion within 28 days post-infusion. Additionally, the long-term efficacy was evaluated, including the improvement of SLEDAI-2K score and achieving lupus low disease activity (LLDAS) at day 180 and day 360, and renal response at day 180 and day 360. The persistence and duration of IM19 CAR-T cells in the peripheral blood of subjects will also be evaluated. The study plan includes five phases: screening phase, cell collection phase, lymphodepletion pretreatment phase, cell infusion phase, and follow-up phase. | Lupus | Non applicable | Thérapie cellulaire | China | À vérifier |
Essais cliniques
4| Molécule | Indication / population | Phase | NCT | Titre | Statut |
|---|---|---|---|---|---|
| IM19 CAR-T cells | Lupus | Non applicable | NCT06513429 | IM19 CAR-T Cell Therapy in Refractory Systemic Lupus Erythematosus (SLE) | RECRUITING |
| Transcranial Magnetic Stimulation | Sclérose latérale amyotrophique | Phase 1 | NCT06819358 | iFIRST-ALS — Individualized Functional Imaging-Guided Repetitive Transcranial Magnetic Stimulation (rTMS) for Treating Postural Gait Disorders in Patients with Amyotrophic Lateral Sclerosis (ALS): a Randomized, Crossover, Controlled, Double-Blind Clinical Study | NOT_YET_RECRUITING |
| Peripheral Neurofilament Levels and Amyotrophic Lateral Sclerosis | Sclérose latérale amyotrophique | À vérifier | NCT04455542 | Peripheral Neurofilament Levels and Amyotrophic Lateral Sclerosis | COMPLETED |
| Natural History and Clinical Features of Amyotrophic Lateral Sclerosis (ALS) | Sclérose latérale amyotrophique | À vérifier | NCT04454892 | Natural History and Clinical Features of Amyotrophic Lateral Sclerosis (ALS) | RECRUITING |
Publications
9| Molécule | Indication / population | Titre | Journal | Date |
|---|---|---|---|---|
| Transcranial Magnetic Stimulation | Treatment of posttraumatic stress disorder (PTSD). | Dialogues in clinical neuroscience | ||
| Transcranial Magnetic Stimulation | A randomized double-blind sham-controlled preliminary study of a 5-week protocol of repetitive transcranial magnetic stimulation (rTMS) combined with cognitive behavioral therapy (CBT) for gambling disorder in Indonesia. | Addictive behaviors reports | ||
| Transcranial Magnetic Stimulation | Assessing the correlation between sensorimotor evoked potential and cognitive impairment in post-stroke patients. | Annals of human biology | ||
| Peripheral Neurofilament Levels and Amyotrophic Lateral Sclerosis | Neutrophil-Secreted Enzymes and ALS Risk: Exploring a Potential Mechanistic Link. | Annals of neurology | ||
| Natural History and Clinical Features of Amyotrophic Lateral Sclerosis (ALS) | Preferences for Healthcare Delivery in Amyotrophic Lateral Sclerosis (ALS): A Survey of Patients and Caregivers in the United States. | The patient | ||
| Peripheral Neurofilament Levels and Amyotrophic Lateral Sclerosis | Silent Damage, Delayed Symptoms: A Case of Breast Cancer Radiation-Induced Lumbosacral Plexopathy. | Reports (MDPI) | ||
| Peripheral Neurofilament Levels and Amyotrophic Lateral Sclerosis | Investigating the role of serum NfL, FGF21, NCAM1 and GDF15 as disease biomarkers for Charcot-Marie-Tooth type 2A. | Scientific reports | ||
| Natural History and Clinical Features of Amyotrophic Lateral Sclerosis (ALS) | Prospective Validation of the New PLS Diagnostic Criteria From PLS Natural History Study: EMG and Neurofilament Analyses. | Muscle & nerve | ||
| Natural History and Clinical Features of Amyotrophic Lateral Sclerosis (ALS) | From Environment to Symptoms: Mapping Premorbid Risk Factors onto Clinical Features of ALS in a Patient-Reported Database in China. | Neurology and therapy |